OPKO Completes Sale of Sorrento Therapeutics Stake

OPKO Health, Inc.

has completed the sale of its stake in Sorrento Therapeutics, Inc.

, a publicly-traded, clinical-stage biopharmaceutical company focused primarily on the acquisition, discovery, development and commercialization of proprietary therapeutics (“Sorrento”). The sale of Sorrento shares adds approximately $22 million to OPKO's cash position and represents an approximate ten-fold return of OPKO's 2009 investment.